Table 7  Specific COVID-19 medications in pregnancy.

Specific medication for COVID-19	Data basis/recommendations for use
Sotrovimab, casirivimab/imdevimab, tixagevimab/cilgavimab (neutralizing monoclonal antibodies)	No associated increased risk of adverse pregnancy outcomes. Data are limited; therefore, no final assessment can be made 63 ,  111 ,  112 ,  113 ,  114 ,  115 ,  116 ,  117 .
Remdesivir (antiviral medicine)	WHO and RCOG recommend that it should be avoided in pregnancy. But because of the low rates of adverse events, administering the drug may be considered if the patient shows signs of clinical deterioration 63 ,  111 ,  118 ,  119 .
Tocilizumab (interleukin-6 receptor inhibitor)	Only limited data available. No indications of teratogenicity or fetotoxicity 63 ,  111 ,  120 ,  121 ,  122 ,  123 .
Molnupiravir (antiviral medicine)	Should not be prescribed 111 .
Nirmatrelvir/ritonavir (Paxlovid, protease inhibitors)	No data on the use of these medications in pregnancy. Must only be administered if potential benefit is clear 124 ,  125 .